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ABSTRACT: Maple syrup urine disease is a rare
metabolic disorder caused by mutations in the branched-
chain a-keto acid dehydrogenase complex gene. Patients
generally present early in life with a toxic encephalopathy
because of the accumulation of the branched-chain
amino acids leucine, isoleucine, and valine and the corre-
sponding ketoacids. Movement disorders in maple syrup
urine disease have typically been described during
decompensation episodes or at presentation in the con-
text of a toxic encephalopathy, with complete resolution
after appropriate dietary treatment. Movement disorders
in patients surviving childhood are not well documented.
We assessed 17 adult patients with maple syrup urine
disease (mean age, 27.5 years) with a special focus on
movement disorders. Twelve (70.6%) had a movement
disorder on clinical examination, mainly tremor and dys-
tonia or a combination of both. Parkinsonism and simple
motor tics were also observed. Pyramidal signs were
present in 11 patients (64.7%), and a spastic-dystonic
gait was observed in 6 patients (35.2%). In summary,
movement disorders are common in treated adult
patients with maple syrup urine disease, and careful neu-
rological examination is advisable to identify those who
may beneﬁt from speciﬁc therapy. VC 2011 Movement Dis-
order Society
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Maple syrup urine disease (MSUD, OMIM
#248600) is a rare inborn error of metabolism caused
by a deﬁciency in the activity of the branched-chain a-
keto acid dehydrogenase (BCKD) complex. As a con-
sequence, the degradation of the 3 branched-chain
amino acids (BCAAs) leucine, isoleucine, and valine is
blocked after the ﬁrst catabolic step (transamination),
resulting in accumulation of BCAAs and the corre-
sponding branched-chain a-keto acids (BCKAs) in bio-
logical ﬂuids.
MSUD is inherited as an autosomal recessive disor-
der, and its worldwide frequency is estimated as
1:185,000,1 although in the Mennonite population of
Lancaster and Lebanon counties in Pennsylvania its
frequency is higher, with a prevalence of approxi-
mately 1 in 176 newborns.2
The human BCKD complex is a multienzymatic
macromolecule composed of 3 catalytic subunits (E1,
with an a2b2 structure, E2, and E3) encoded by differ-
ent genes located on chromosomes 19, 6, 1, and 7,
respectively. Mutations in each of these loci are re-
sponsible for different molecular phenotypes indicated
as type IA (E1a), type IB (E1b), type II (E2), and type
III (E3).1 Depending on the clinical presentation and
the residual enzymatic activity of BCKD, 5 phenotypes
are recognized: classic, intermediate, intermittent, thia-
mine responsive, and E3 deﬁcient.1,3 Classic MSUD is
the most common form, and affected newborns
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present with lethargy, poor sucking, and rapidly pro-
gressive encephalopathy in the ﬁrst days of life, when
the characteristic odor of burnt sugar may be noted.
Alterations of muscular tone and abnormal dystonic
extensions of the arms can occur during this stage of
disease.4 Increased blood, urine, and cerebrospinal
ﬂuid BCAAs (especially leucine) are found during
acute metabolic decompensation, often provoked by
intercurrent illness, fasting, injury, or surgery and con-
tributed to by endogenous protein catabolism.
Patients with MSUD later on may develop neurolog-
ical sequelae such as spasticity and quadriplegia as a
consequence of the damage resulting from widespread
cerebral edema at ﬁrst clinical presentation or during
decompensation episodes.5
Movement disorders can be part of the manifesta-
tions of various metabolic diseases,6 alone or in com-
bination with other neurological ﬁndings. An
increasing number of individuals with MSUD are sur-
viving childhood thanks to a BCAA-restricted diet, but
little information on the prevalence of movement dis-
orders in these adults is available. We present the clin-
ical neurological ﬁndings of 17 adult patients with
MSUD, with a particular emphasis on the spectrum of
movement disorders.
Patients and Methods
Seventeen patients (11 women, 6 men; mean age,
27.5 years) diagnosed with MSUD followed up at the
Charles Dent Metabolic Unit, National Hospital for
Neurology and Neurosurgery, London, were reviewed.
This is a tertiary adult referral centre with close links
to the pediatric service where patients with MSUD are
followed up until age 16 after initial diagnosis.
Relevant details about patients’ medical history were
obtained from their ﬁles and by direct questioning of ei-
ther the patients themselves or their caregivers. All
patients underwent a full neurological examination by
a single neurologist, along with metabolic follow-up
including determination of plasma BCAAs.
Thirteen patients were diagnosed with classic, 2 with
intermittent, and 2 with intermediate MSUD. Disease
duration at the time of examination ranged from 17 to
48 years (mean, 27 years), and all but 2 classic cases
were diagnosed within the ﬁrst 3 weeks of life. The 4
nonclassic cases were diagnosed between 2 and 4 years
of age. In all patients, the diagnosis of MSUD was
based on clinical suspicion and conﬁrmed by measuring
elevated BCAA levels in blood and urine. Genetic anal-
ysis was not routinely included in the diagnostic
workup. One Ashkenazi Jewish patient was tested on a
research basis and was found to carry a previously
described homozygous mutation (c.548G>C,
p.Arg183Pro) in exon 5 of the BCKDHB gene, encod-
ing the E2-b subunit of the BCKD complex.
Patients with classic MSUD were all on a protein-re-
stricted diet (mean protein intake, 9.8 g/day) and
amino acid supplementation, whereas 3 of the 4
nonclassic cases were on an unrestricted diet, and 1
followed a vegetarian diet.
Demographic data of the patients are shown in Table 1.
Results
Twelve of 17 patients (70.6%) had a movement dis-
order detectable on clinical examination. Tremor was
TABLE 1. Demographic features of MSUD patients
Patient number Sex Age
Movement
disorder
Disease
duration (y) Diet
Daily protein
intake (g)
1 F 23 Y 23 Y 5
2 M 27 Y 27 Y 5.5
3 M 18 N 18 Y 8
4 F 31 N 31 Y 8
5 F 17 Y 17 Y 8
6 F 25 Y 25 Y 8
7 F 33 Y 33 Y 10
8 F 27 N 27 Y 10
9 M 20 Y 20 Y 11
10 F 31 Y 31 Y 12
11 M 33 Y 33 Y 12
12 F 48 Y 48 Y 18
13 M 26 Y 26 Y 12
14a F 30 N 28 N Unrestricted
15a M 25 Y 23 N Unrestricted
16a F 25 Y 25 N Unrestricted
17a F 29 N 25 N Vegetarian
Total 11 F 6 M 27.5 (mean) 12 Y 5 N 27 (mean) 11 Y 6 N 9.8 (mean)
aNonclassic MSUD patients.
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present in 7 subjects (41.1%), alone (1 case) or in
combination with other movement disorders: dystonia
in 6 (35.3%), parkinsonism in 3 (17.6%; see Video
Segment 3), and simple motor tics in 1 (5.9%).
Among the patients with a movement disorder (n ¼
11), tremor and dystonia were the most common ﬁnd-
ings on examination, being detected in 63.6% and
54.5% of subjects, respectively. Of these, 3 patients
(27.2%) exhibited a tremor at rest (asymmetric in 2
cases, symmetric in 1 case), 5 patients (45.5%) a pos-
tural tremor, and 2 patients (18%) an intention
tremor. Among patients with dystonia, 5 (45.5%) had
a dystonic posture affecting the hands and 3 (27.2%)
the feet, presenting as bilateral plantar ﬂexion and
inversion in 1 case and as part of a scissoring-dystonic
gait in 2 cases (see Video Segments 1 and 2), and 2
cases (18%) displayed cervical dystonia. Four of 5
patients with dystonia also had a tremor in the
affected part of the body, suggesting a dystonic
tremor. All patients with parkinsonism presented bra-
dykinesia on ﬁnger tapping (symmetric in 1 patient,
asymmetric in 2 patients) with no rest tremor. One
patient showed additional features including facial
hypomimia and poverty of movements, loss of pos-
tural reﬂexes, and bilateral reduction of arm swings,
along with cogwheel rigidity in the left upper limb.
In 1 case simple motor tics were detected on exami-
nation, manifesting as brief neck rotations to the left,
which were partially suppressible with distraction, but
we cannot exclude that this ﬁnding was incidental. In
all patients the distribution of movement disorders
was in the upper part of the body, with additional
involvement of the lower limbs in 3 cases. Table 2
summarizes the movement disorders found in the
patients examined.
In addition to movement disorders, pyramidal signs
such as brisk reﬂexes and spasticity were frequent on
examination, overall being present in 11 patients
(64.3%). Six showed a scissoring-dystonic gait and
were signiﬁcantly disabled. Language impairment was
present in 6 of 17 patients (35.2%), including spastic
dysarthria in 4 and slurred speech in 2. Four patients
(23.5%) had epilepsy that required pharmacological
treatment. Neuropsychiatric disturbances including
depression and obsessive-compulsive disorder were
present in 2 subjects (11.7%), whereas various degrees
of learning difﬁculties with mental retardation were
shown in 10 of 17 cases (58.8%).
Discussion
In this observational study, we describe the spectrum
of movement disorders in adults with MSUD. MSUD is
a rare metabolic disorder that generally presents with a
toxic encephalopathy within the ﬁrst days of life. Long-
term outcomes in treated adult patients have been difﬁ-
cult to establish because of the rarity of the disorder
and its severity on initial presentation, often leading to
premature death. It is well recognized that various
movement disorders can be present in metabolic condi-
tions, often being secondary to early cerebral damage,3
but the spectrum of movement disorders in MSUD is
unknown. Although we have previously described neu-
ropsychometric outcomes in some patients included in
this study,7 no detailed studies have been published on
long-term motor signs.
In our series of 17 patients, more than two thirds
exhibited a movement disorder on clinical examina-
tion, mainly tremor and dystonia or a combination of
both. These were present in the upper limbs in all
cases, with additional involvement of the neck in 2
patients and of the lower limbs in 3 patients. Aside
from movement disorders, the most common neuro-
logical ﬁndings were pyramidal signs in the lower
limbs and learning difﬁculties, observed in 64.7% and
58.8% of cases, respectively. The combination of dys-
tonia and spasticity in the lower limbs was the most
disabling clinical ﬁnding, signiﬁcantly reducing
patients’ ability to walk independently and thus inter-
fering with their quality of life.
To date, movement disorders in MSUD have only
been described as part of the symptoms at onset in the
context of a toxic encephalopathy, as recurrent parox-
ysmal ataxia or paroxysmal dystonia in intermittent
variant MSUD, and during episodes of decompensa-
tion.1,8,9 In these cases, movement disorders tended to
resolve after appropriate dietary treatment.
In our series of adult patients, many had a persistent
movement disorder, even when on a strict dietary regi-
men in the absence of intercurrent metabolic decom-
pensation. Interestingly, we did not observe major
cerebellar signs such as ataxia, as previously reported,3
at presentation or during decompensation episodes
TABLE 2. Neurological ﬁndings in adult
patients with MSUD
Clinical ﬁnding Type Number (percentage)
Movement
disorders (12
of 17 patients)
Tremor 7 (41.1%)
—At rest 3
—Postural 5
—Intention 2
Dystonia 6 (35.3%)
—Cervical 2
—Upper limbs 5
—Lower limbs 3
Parkinsonism 3 (17.6%)
Other movement disorders 1 (5.9%)
Other neurological
ﬁndings (11 of
17 patients)
Pyramidal signs 11 (64.7%)
Scissoring-dystonic gait 6 (35.2%)
Language impairment 6 (35.2%)
Neuropsychiatric disturbances 2 (11.7%)
Cognitive impairment 10 (58.8%)
Epilepsy 4 (23.5%)
C A R E C C H I O E T A L .
1326 Movement Disorders, Vol. 26, No. 7, 2011
consistent with a typical severe cerebellar edema seen
on neuroimgaing10 and with prominent neuropatho-
logical alterations in the cerebellum.1
There is considerable interest in movement disorders
due to metabolic diseases, as this can provide some
answers with regard to pathophysiology, as recently
exempliﬁed by Gaucher’s disease–related parkinson-
ism. Our clinical observations raise the question of the
nature of the underlying pathophysiology of move-
ment disorders seen in adult MSUD patients. With
regard to the neuropathology, it is known that in
MSUD considerable neuronal loss is present in the
pontine nuclei and substantia nigra,11 and striatal
damage has been demonstrated both in the animal
model of MSUD12 and in affected children.4
Moreover, leucine has a high afﬁnity for the L1-neu-
tral amino acid transporter through which other
amino acids are transported into the central nervous
system; therefore, high leucine plasma concentrations
reduce the uptake of some amino acids in the brain,
including phenylalanine, tyrosine, and tryptophan.
This leads to the depletion of some neurotransmitters
in the brain such as dopamine and serotonin, as dem-
onstrated in the animal model of MSUD by Zinnanti
et al,13 who observed a reduction in dopamine levels
in the brain of MSUD mice by more than 60% along
with decreased GABA and glutamate levels. The
depletion of neurotransmitters, especially dopamine,
was concomitant with the initiation of limb dystonia
and gait abnormalities in MSUD mice.
Although these ﬁndings were described during acute
encephalopathy, it is possible that altered neurotrans-
mitter levels, especially dopamine, are present as a long-
term consequence in the brains of adult MSUD patients,
being responsible for the development of dystonia, as
seen in other diseases characterized by reduced dopa-
mine availability (juvenile Parkinson’s disease, dopa-re-
sponsive dystonia).14,15 Interestingly, in a series of 36
infants, dystonia was observed at onset in 42.2% of
patients, being associated with high serum leucine-to-
tyrosine ratios and thus further suggesting that acute
leucinosis with secondary tyrosine deﬁciency may con-
tribute to the development of dystonia.4
Finally, the development of movement disorders in
MSUD mice has been further explained by a disrup-
tion of the cerebral energy metabolism from the toxic
effect of BCKA in the central nervous system with
reduced ATP and phosphocreatine levels,13 which may
affect the normal functioning of basal ganglia and
other parts of the brain highly dependent on the mito-
chondrial respiratory chain.
In addition to these neurochemical changes that may
at least be partly responsible for the movement disor-
ders observed in our patients, the permanent damage
resulting from early encephalopathy at onset is likely
to play a role in the development of movement disor-
ders. In this regard, 3 of our patients with a move-
ment disorder (parkinsonism; rest tremor; dystonia
and spastic-dystonic gait) underwent a brain MRI
scan that did not show any abnormality of either the
basal ganglia or the cerebellum. However, we cannot
exclude that other patients included in our series
might have a structural damage on neuroimaging.
It may be that given the above-mentioned biochemi-
cal alterations, the development of movement disor-
ders in MSUD is associated with the number as well
as the severity of decompensation episodes. However,
in our series it was not possible to clearly deﬁne the
total number of decompensation episodes throughout
life, as not all resulted in hospital admission or were
clearly documented.
With regard to the treatment of movement disorders,
symptomatic drugs such as local botulinum toxin injec-
tions in patients with dystonia or dopaminergic drugs in
those with parkinsonism should be considered as poten-
tial treatments in the future. No cases of deep brain
stimulation (DBS) in patients with MSUD and move-
ment disorder have been reported so far, but DBS has
been successfully used in a few cases of other inborn
errors of metabolism also presenting with movement
disorders such as Lesh-Nyhan syndrome.16,17
Conclusions
Movement disorders have been described in MSUD
at onset or during decompensation episodes, mainly as
paroxysmal dystonia or ataxia. In this study, we
assessed 17 adult patients with MSUD and observed a
high prevalence of movement disorders, even in
patients with a long disease duration following a pro-
tein-restricted diet and under relatively stable meta-
bolic control. Dystonia in the upper limbs and tremor
were the most frequent ﬁndings. We speculate that
these symptoms may be secondary to cerebral damage
from toxic encephalopathy at onset and during recur-
rent acute decompensation and/or chronic reduced lev-
els of neurotransmitters, such as dopamine, as
demonstrated in the animal model of MSUD.
Our ﬁndings suggest that a careful neurological
assessment is advisable in adult patients with MSUD,
and we recommend screening these patients for move-
ment disorders such as dystonia and parkinsonism, as
these symptoms are potentially treatable. Further stud-
ies are needed to clarify the pathophysiology of move-
ment disorders in MSUD in order to offer patients
speciﬁc treatments to improve their quality of life.
Legends to the Video
Video Segment 1. Seventeen-year-old patient. Dys-
tonic posture of feet (inversion) with gait showing
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mixed dystonia and spasticity. Cervical dystonia (left
torticollis, mild retrocollis, and left shoulder eleva-
tion). Mild dystonic posture of the right hand, with
slowness in performing ﬁnger tapping bilaterally with-
out evidence of clear decrement.
Video Segment 2. Thirty-one-year-old patient. Dys-
tonic posture of feet and toes and a gait with a mixture
of dystonia and spasticity. A bilateral dystonic posture
of both hands, more marked on the right side, is visible
on walking and keeping arms outstretched. Mild cervi-
cal dystonia (right torticollis) is also detectable.
Video Segment 3. Thirty-year-old patient. Slow gait
with reduced arm swings bilaterally. Hypomimia, poverty
of movements, and left bradykinesia on ﬁnger tapping.
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